ADC Therapeutics Announces $86.6M Financing And Debt Restructuring; Stock Up

ADC Therapeutics raised $86.6M via private placement, amended its Blue Owl loan to prepay $70M and retain $50M, and revised its HCR Royalty deal to add a buyout option and reduce debt capacity. The moves aim to improve liquidity and flexibility.

ADC Therapeutics SA (ADCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements $86.6 Million Private Placement announced, with participation from new and existing investors, extending expected cash runway into 2029 HealthCare Ro

ADC Therapeutics (ADCT) is restructuring financially, raising $86.6M via a private placement from existing investors. The move is expected to extend its cash runway into 2029, according to the company.

ADC Therapeutics (ADCT) raised $86.6M via private placement, selling shares and warrants. It restructured debt, extending cash runway to 2029. Q3 ZYNLONTA revenue was $21M, with $189.2M cash as of September 30, 2026. Proceeds will fund pipeline studies, including Phase 3 trials.

ADC Therapeutics (ADCT) reported Q2 earnings with steady ZYNLONTA revenue at $18.6M and reduced net loss to $16.6M. The FDA raised safety concerns about a combination trial, creating regulatory uncertainty. The company cut operating expenses by 29% and has cash to last into 2028. Short interest is at 5.70% of the float.

ADC Therapeutics SA (ADCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026 LOTIS-7, LOTIS-5 and MZL IIT data submitted for p